This trial will provide continued lorlatinib treatment and safety monitoring to those who benefit from it, to further understand its safety profile.
- Non-Small Cell Lung Cancer
2 Primary · 0 Secondary · Reporting Duration: Baseline up to approximately 5 years
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
200 Total Participants · 1 Treatment Group
Primary Treatment: Lorlatinib · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the capacity of this experiment in terms of participants?
"Affirmative. Clinicaltrials.gov displays that this medical trial, which appeared on December 28th 2021 remains active and is currently recruiting participants. 200 individuals are being enrolled from a single medical centre." - Anonymous Online Contributor
Could you please elucidate the potential risks associated with Lorlatinib?
"Lorlatinib has already been approved by the FDA, so its safety level is rated a 3." - Anonymous Online Contributor
Is this clinical research program currently enrolling participants?
"According to information hosted on clinicaltrials.gov, enrollment is presently ongoing for this medical trial which was first publicized on December 28th 2021 and last revised on February 22nd 2023." - Anonymous Online Contributor
Does this clinical research represent a pioneering effort?
"Presently, 17 trials for Lorlatinib are being conducted in 440 cities and 26 nations. The pioneer investigation of this drug occurred in 2016 when Amgen sponsored a trial with 1550 participants which eventually culminated in Phase 2 FDA clearance. Since then, 12 such studies have been completed." - Anonymous Online Contributor
Has any other experimentation been done with Lorlatinib?
"Currently, there are 17 ongoing lorlatinib clinical trials with 1 in the third stage of testing. Broadly based out of Boston, Massachusetts these tests can be found at 901 different medical sites around the world." - Anonymous Online Contributor